Clinical Trial: A Study of LY4515100 in Healthy Participants

U.S., Jan. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07339722) titled 'A Study of LY4515100 in Healthy Participants' on Jan. 06.

Brief Summary: The main purpose of this study is to assess the safety and tolerability of LY4515100 when given orally to healthy participants. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will last up to 30 days and will include six overnight stays.

Study Start Date: Jan., 2026

Study Type: INTERVENTIONAL

Condition: Healthy

Intervention: DRUG: LY4515100 via SAD

given orally

DRUG: LY4515100 via MAD

given orally

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Eli Lilly and Company...